About CAVERJECT IMPULSE Treatment Optimization Physician Resources and Product Samples

Prescribing Information | Safety Information *A 6-month, open-label study in 683 men, mean age 58 years, to determine the optimum dose of CAVERJECT IMPULSE.

Important Safety Information
CAVERJECT IMPULSE is indicated for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.

The most common side effect of CAVERJECT IMPULSE was penile pain, reported by 37% of patients in clinical studies. Only 3% discontinued CAVERJECT IMPULSE for this reason.

CAVERJECT IMPULSE should not be used in men hypersensitive to alprostadil, men with conditions that may predispose them to priapism, men with anatomical deformities of the penis, men with penile implants, or men for whom sexual activity is not advisable or is contraindicated. Penile fibrosis, including Peyronie's disease, was reported in clinical trials with CAVERJECT IMPULSE.

Patients should be instructed to report any erection lasting 4 hours or longer. Treatment of priapism should not be delayed more than 6 hours.

Each patient should be titrated to the lowest effective dose.

The product information in this site is intended only for residents of the United States.